News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
680,078 Results
Type
Article (39363)
Company Profile (254)
Press Release (640461)
Section
Business (203805)
Career Advice (1989)
Deals (35372)
Drug Delivery (78)
Drug Development (80726)
Employer Resources (167)
FDA (16030)
Job Trends (14836)
News (344128)
Policy (32438)
Tag
Academia (2556)
Africa (711)
Alliances (49059)
Alzheimer's disease (1150)
Approvals (15952)
Arizona (173)
Artificial intelligence (69)
Asia (36870)
Australia (6010)
Bankruptcy (350)
Best Places to Work (11300)
Biosimilars (63)
Biotechnology (178)
C2C Services and Suppliers (78870)
California (1789)
Canada (908)
Cancer (398)
Career advice (1655)
Cell therapy (114)
China (136)
Clinical research (63178)
Collaboration (129)
Colorado (71)
Compensation (73)
Connecticut (69)
COVID-19 (2487)
Cystic fibrosis (72)
Data (228)
Diabetes (79)
Diagnostics (5966)
Drug pricing (61)
Earnings (83684)
Employer resources (142)
Europe (78917)
Events (107941)
Executive appointments (137)
FDA (16228)
Florida (255)
Funding (135)
Gene therapy (88)
GLP-1 (510)
Government (4292)
Healthcare (18633)
Hotbed/Location (481532)
Illinois (249)
Indiana (145)
Infectious disease (2514)
Inflammatory bowel disease (88)
Interviews (309)
IPO (16198)
Job creations (3633)
Job search strategy (1420)
Kansas (94)
Layoffs (394)
Legal (7837)
Lung cancer (90)
Manufacturing (82)
Maryland (375)
Massachusetts (1460)
Medical device (13049)
Medtech (13054)
Mergers & acquisitions (19020)
Metabolic disorders (240)
Michigan (123)
Minnesota (213)
Neuroscience (1287)
New Jersey (541)
New York (563)
NextGen Class of 2024 (6501)
Non-profit (4464)
North Carolina (579)
Northern California (794)
Obesity (143)
Ohio (103)
Opinion (172)
Patents (66)
Pennsylvania (566)
People (55921)
Pharmaceutical (62)
Phase I (19573)
Phase II (27823)
Phase III (20786)
Pipeline (103)
Postmarket research (2550)
Preclinical (8337)
Press Release (64)
Rare diseases (127)
Real estate (5897)
Recruiting (63)
Regulatory (21187)
Research institute (2324)
Resumes & cover letters (347)
South America (1087)
Southern California (725)
Startups (3572)
Texas (223)
United States (8209)
Vaccines (463)
Washington State (245)
Weight loss (124)
Date
Today (5)
Last 7 days (657)
Last 30 days (2092)
Last 365 days (37190)
2024 (25728)
2023 (40159)
2022 (51251)
2021 (55796)
2020 (54158)
2019 (46605)
2018 (35090)
2017 (32175)
2016 (31586)
2015 (37658)
2014 (31432)
2013 (26464)
2012 (28658)
2011 (29324)
2010 (27378)
680,078 Results for "minerva neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.
May 1, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 6, 2024
·
6 min read
Business
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
February 22, 2024
·
6 min read
Genetown
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
February 27, 2024
·
6 min read
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
·
2 min read
·
Tyler Patchen
Business
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the third quarter ended September 30, 2023.
November 7, 2023
·
6 min read
Business
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the second quarter ended June 30, 2023.
August 1, 2023
·
7 min read
Business
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
7 min read
Deals
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Minerva Neurosciences, Inc. today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant.
June 28, 2023
·
4 min read
Business
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023Management to Host Conference Call
Minerva Neurosciences, Inc. today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023.
May 8, 2023
·
1 min read
1 of 68,008
Next
